Quarterly ResultMay 18, 2026, 07:02 AM
NRX Pharmaceuticals Advances Ketamine Approval, Acquires Geneuro Assets
AI Summary
NRX Pharmaceuticals announced significant progress in Q1 2026, advancing its drug candidates towards commercialization and expanding its therapeutic platform. The company anticipates an FDA decision on its Preservative-Free Ketamine ANDA in Q3 2026 and has initiated commercial manufacturing. Additionally, NRx is set to acquire Geneuro, SA assets, broadening its pipeline, and reported a reduced net loss of $1.4 million for the quarter.
Key Highlights
- Anticipated FDA decision on Preservative-Free Ketamine ANDA in Q3 2026, with favorable preliminary determinations.
- Initiated commercial manufacturing of Ketamine at 1 million doses per month, with FDA inspection status consistent with launch.
- Pending acquisition of Geneuro, SA assets, including patent portfolio and Phase 2 data, expected to close Q2 2026.
- FDA accepted IND for NRX-101 Phase 2b/3 MIND1 trial as adjunct to robotic TMS, with anticipated federal funding.
- Reported Q1 2026 net loss of $1.4 million, improved from $5.5 million loss in Q1 2025.
- Q1 2026 net operating loss was $4.7 million, compared to $3.8 million in Q1 2025, due to strategic investments.
- Cash and cash equivalents totaled $6.7 million as of March 31, 2026.
- HOPE Therapeutics expanded to five interventional psychiatry clinics, targeting eight+ locations by Q2 2026.
Price Impact
More from NRXP